Study on Management Thrombosis in Greek Cancer Patients (GMaT)

Study on Management Thrombosis in Greek Cancer Patients (GMaT - Greek Management Thrombosis)

Study on Management Thrombosis in Greek cancer patients

Study Overview

• Status: Completed
• Conditions: Thrombosis

Detailed Description

The approach that Medical Oncologists encounter the prospect of a coagulation event occurrence in cancer patients.

• Study Type: Observational
• Enrollment (Actual): 500

Contacts and Locations

Study Locations

• Greece
  • Athens, Greece, 11475
    • Hellenic Society of Medical Oncology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with solid tumors under anticoagulation regime, for prophylaxis or treatment.

Description

Inclusion Criteria

• All patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline.
• Age ≥ 18 years
• Signed informed consent

Exclusion Criteria

• Initiation of anticoagulation therapy before the initiation of the study in 2016
• Age <18 years
• No signed informed consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The clinical practice for patients under anticoagulation regime	Documentation of the clinical practice for patients under anticoagulation regime, for prophylaxis or treatment, in patients with solid tumors, for one year following the protocol initiation date, including high-risk patients as defined in the protocol.	1 YEAR

Collaborators and Investigators

• Sponsor: Hellenic Society of Medical Oncology
• Investigators: Principal Investigator: Ioannis Varthalitis, MD, Hellenic Society of Medical Oncology

Publications and helpful links

General Publications

• Christopoulou A, Ardavanis A, Papandreou C, Koumakis G, Papatsimpas G, Papakotoulas P, Tsoukalas N, Andreadis C, Samelis G, Papakostas P, Aravantinos G, Ziras N, Souggleri M, Kalofonos C, Samantas E, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Bokas A, Grivas A, Tripodaki ES, Varthalitis I, Timotheadou E, Boukovinas I. Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence. Oncol Lett. 2022 Apr;23(4):115. doi: 10.3892/ol.2022.13235. Epub 2022 Feb 9.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2016
• Primary Completion (Actual): December 31, 2017
• Study Completion (Actual): February 28, 2018

Study Registration Dates

• First Submitted: September 20, 2017
• First Submitted That Met QC Criteria: September 20, 2017
• First Posted (Actual): September 25, 2017

Study Record Updates

• Last Update Posted (Actual): April 5, 2019
• Last Update Submitted That Met QC Criteria: April 4, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Embolism and Thrombosis; Thrombosis
• Other Study ID Numbers: Management Thrombosis

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No